<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139497">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837082</url>
  </required_header>
  <id_info>
    <org_study_id>iCHF_D.3874</org_study_id>
    <secondary_id>2012-001134-33</secondary_id>
    <nct_id>NCT01837082</nct_id>
  </id_info>
  <brief_title>Iron in Congestive Heart Failure</brief_title>
  <acronym>iCHF</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis to be tested is whether treatment with intravenous iron (ferric
      carboxymaltose) will improve left-ventricular ejection fraction in patients with heart
      failure and iron deficiency as determined by cardiac magnetic resonance imaging.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary endpoint of the study is the change from baseline to week 12 in left-ventricular ejection fraction as determined by cardiac magnetic resonance imaging.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <condition>Iron Deficiency</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ferric carboxymaltose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride 0.9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferric carboxymaltose</intervention_name>
    <arm_group_label>Iron</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sodium chloride 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Congestive heart failure

          -  At least 18 years of age

          -  Iron deficiency

          -  Dyspnea class II or III according to New York Heart Association

          -  Left-ventricular ejection fraction â‰¤ 45%

        Exclusion Criteria:

          -  Known sensitivity to any of the products to be administered during dosing

          -  Immediate need of transfusion

          -  Patients presenting with an active infection

          -  Thalassaemia

          -  Other forms of microcytic anemia not caused by iron deficiency

          -  History of acquired iron overload

          -  Need for revascularization, ST-segment elevation myocardial infarction or
             Non-ST-segment elevation myocardial infarction during the past 3 months (at time of
             randomization)

          -  Women who are pregnant or of childbearing age and not using medically acceptable
             effective contraception
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahir Karakas, MD</last_name>
    <phone>+49-731-50045075</phone>
    <email>mahir.karakas@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Brandenburg, MD</last_name>
      <phone>+49-241-8085709</phone>
      <email>vbrandenburg@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Vincent Brandenburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahir Karakas, MD</last_name>
      <phone>+49-731-50045075</phone>
      <email>mahir.karakas@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Mahir Karakas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 17, 2013</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Dr. Mahir Karakas</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Iron Deficiency</keyword>
  <keyword>Anemia</keyword>
  <keyword>Ferric Carboxymaltose</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
